RecruitingPhase 1NCT07205289

Serum Collection Study for Assay Development

A Phase 1B Open-label Study to Collect Serum Following Vaccination With Killed Whole-cell Pneumococcal Vaccine (Gamma-PN) in Adults for Use in Assay Validation

Sponsor

GPN Vaccines

Enrollment

12 participants

Start Date

Oct 1, 2025

Study Type

INTERVENTIONAL

Conditions

Pneumococcal Disease, Invasive Pneumococcal disease

Summary

The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation

Eligibility

Min Age: 18 YearsMax Age: 69 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Gamma-PN for people with pneumococcal disease, invasive and pneumococcal disease. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 69 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.